Mixed Signals Despite Missed Primary Endpoint

NMD Pharma's ignaseclant (NMD670), an ion channel ClC-1 inhibitor under development without a brand name, was evaluated in 81 patients with CMT1 and CMT2 in the randomized, double-blind Phase 2a SYNAPSE-CMT trial. The 6-minute walk test (6MWT) at Day 21 showed no significant difference compared to placebo, failing to meet the pre-specified primary endpoint. However, grip strength improved with p=0.02 at Day 21 and p<0.01 at Day 28, and signals were also observed in the CMT Functional Outcome Measure (CMT-FOM) and patient-reported outcomes, suggesting potential for mechanisms that enhance muscle responsiveness rather than direct nerve repair.

Trial Design Shapes Asset Value

CMT is caused by over 1,000 mutations in more than 80 genes and affects approximately 1 in 2,500 people globally, yet no FDA-approved disease-modifying therapies are currently available. Standard care remains limited to physical therapy, braces, and mobility aids, making tools that capture hand function and daily life changes more relevant than short-term 6MWT assessments. The results of ignaseclant indicate the need to re-evaluate patient populations, treatment duration, and primary endpoints in future trials. Publication of peer-reviewed detailed results will be the next critical step in assessing reproducibility and development pathways.

Leadership Shifts After Front-Runner Failures

Pharnext's PXT3003, a combination of baclofen, naltrone hydrochloride, and sorbitol targeting PMP22 overexpression in CMT1A, failed to improve functional mobility in Phase 3, leading to the company's forced liquidation in August 2024. Applied Therapeutics' govorestat (AT-007), an aldose reductase inhibitor for CMT-SORD, missed its 12-month 10-meter walk and running primary endpoints in Phase 3 and was acquired by Cycle Pharmaceuticals in November 2024 after an NDA supplement for classic galactosemia. Clinical trials were halted in April 2026. These repeated failures highlight how peripheral nerve barriers, genetic heterogeneity, and short-term functional variability increase both development costs and capital-raising risks for CMT.

RNA and Precision Therapy Pipelines Are Catching Up

Novartis (NVS)'s EDK060, previously known as DTx-1252, is a PMP22-targeting siRNA with FDA orphan drug designation, entering Phase 1 for CMT1A. Novartis acquired DTx Pharma for up to USD 1 billion in 2023 to secure this asset and the FALCON delivery platform. Actio Biosciences' TRPV4 channel inhibitor ABS-0871 is in Phase 1b for CMT2C, while Vanda Pharmaceuticals (VNDA)'s IGHMBP2 splicing-targeting ASO VCA-894A is in a single-patient, customized Phase 1 trial and received FDA orphan pediatric disease designation on July 7, 2026. Helixmith (084990)'s engensis (VM202), an HGF-expressing plasmid gene therapy, is in Phase 1 for CMT1, with clinical competition now spanning muscle activation, RNA inhibition, and gene delivery approaches.